Integra LifeSciences Holdings Corporation announced its financial results for the first quarter ending March 31, 2025. The company reported total revenues of $382.7 million, an increase of 3.7% on a reported basis but a decline of 3.5% organically compared to the prior year. GAAP net loss for the quarter was $(25.3) million, or $(0.33) per diluted share, compared to a GAAP net loss of $(3.3) million, or $(0.04) per diluted share, in Q1 2024.
Adjusted net income for the first quarter was $31.7 million, or $0.41 per diluted share, down from $43.0 million, or $0.55 per diluted share, in the prior year. GAAP gross margin decreased to 50.8% from 56.1% in Q1 2024, and adjusted gross margin was 62.2% compared to 64.4%. The company noted ongoing efforts to strengthen quality systems and improve supply reliability, with significant work remaining on its Compliance Master Plan.
For the full year 2025, Integra LifeSciences reaffirmed its revenue guidance range of $1.650 billion to $1.715 billion, representing reported growth of 2.4% to 6.5% and organic growth of 0.4% to 4.4%. However, the company reduced its adjusted EPS guidance to a range of $2.19 to $2.29 per share, primarily due to an estimated $(0.22) per share impact from new tariffs. Second-quarter 2025 revenue is projected between $390 million and $400 million, with adjusted EPS of $0.40 to $0.45.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.